Literature DB >> 7774310

Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma.

C S Park1, S M Lee, S W Chung, S Uh, H T Kim, Y H Kim.   

Abstract

To clarify the interrelation between interleukin-2 (IL-2) and soluble IL-2R receptor (sIL-2R), as products of T-cell activation in the bronchial tree of patients with bronchial asthma, we measured the concentration of IL-2, sIL-2R, and the cellular composition in bronchoalveolar lavage (BAL) fluid. We also measured physiologic parameters, including provocation concentration of histamine required to reduce the forced expiratory volume in 1 s by 20 percent of the prechallenge baseline (PC20). The concentrations of IL-2 and sIL-2R were higher in BAL fluid of symptomatic patients with bronchial asthma than those of normal subjects and asymptomatic patients. There was a significant correlation between IL-2 and sIL-2 concentrations in BAL fluid of the patients with bronchial asthma. Patients with other lung diseases had significantly higher concentration of IL-2 than normal control; however, sIL-2R was not detected in their BAL fluids. The concentration of IL-2 inversely correlated with FEV1 in symptomatic bronchial asthma. Among the inflammatory cells in BAL fluid, percentages of eosinophils showed significant correlation with the concentrations of IL-2 and sIL-2R in BAL fluid of the patients with bronchial asthma. In conclusion, IL-2 within the bronchial tree appears to be associated with eosinophil infiltration. This leads to physiologic changes in symptomatic patients with bronchial asthma, which may be influenced by the presence of sIL-2R in BAL fluid.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7774310     DOI: 10.1378/chest.106.2.400

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Testosterone Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation.

Authors:  Jacqueline-Yvonne Cephus; Matthew T Stier; Hubaida Fuseini; Jeffrey A Yung; Shinji Toki; Melissa H Bloodworth; Weisong Zhou; Kasia Goleniewska; Jian Zhang; Sarah L Garon; Robert G Hamilton; Vasiliy V Poloshukin; Kelli L Boyd; R Stokes Peebles; Dawn C Newcomb
Journal:  Cell Rep       Date:  2017-11-28       Impact factor: 9.423

Review 2.  Monoclonal antibodies for the treatment of severe asthma.

Authors:  Salvatore Clienti; Jaymin B Morjaria; Elisa Basile; Riccardo Polosa
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

3.  Unusual asthma syndromes and their management.

Authors:  Jaymin B Morjaria; Jack A Kastelik
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

4.  Recommendation for optimal management of severe refractory asthma.

Authors:  Jaymin B Morjaria; Riccardo Polosa
Journal:  J Asthma Allergy       Date:  2010-07-26

5.  IL-2 modulates Th2 cell responses to glucocorticosteroid: A cause of persistent type 2 inflammation?

Authors:  Tharsan Kanagalingam; Lauren Solomon; Meerah Vijeyakumaran; Nami Shrestha Palikhe; Harissios Vliagoftis; Lisa Cameron
Journal:  Immun Inflamm Dis       Date:  2019-04-17

6.  Increased Serum Soluble Interleukin-2 Receptor Associated with Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Yue Zhang; Lianping Ren; Jinyuan Sun; Fengfeng Han; Xuejun Guo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.